Real-World Outcomes of Polatuzumab Vedotin Plus R-CHP Versus R-CHOP-Based Regimens in Japanese Patients With...

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (PV-R-CHP) is a new regimen for untreated diffuse large B-cell lymphoma (DLBCL).
• Limited real-world data exists comparing PV-R-CHP to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

Purpose of the Study:

• To evaluate the real-world efficacy and safety of PV-R-CHP versus R-CHOP-based regimens in newly diagnosed DLBCL patients.
• To compare progression-free survival (PFS), overall survival (OS), and adverse events between the two treatment groups.

Main Methods:

• Retrospective analysis of 153 newly diagnosed DLBCL patients treated with PV-R-CHP or R-CHOP as first-line therapy.
• Propensity score matching was used to control for confounding factors.
• Primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS) and response rates.

Main Results:

• PV-R-CHP demonstrated significantly higher 1-year PFS (89.3% vs. 70.9%) and OS (92.5% vs. 80.0%) compared to R-CHOP.
• Complete response rates were similar (81.1% vs. 76.0%).
• PV-R-CHP showed improved PFS in non-germinal center B-cell-like (non-GCB) DLBCL, with comparable rates of grade ≥3 adverse events.

Conclusions:

• PV-R-CHP may offer superior survival outcomes over R-CHOP in newly diagnosed DLBCL, especially for the non-GCB subtype.
• The regimen exhibits an acceptable safety profile in a real-world setting.
• Further follow-up is needed to confirm long-term durability, supporting PV-R-CHP as a frontline option.